This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shakespeare, W. A.
Right arrow Articles by Petti, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shakespeare, W. A.
Right arrow Articles by Petti, C. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2005, p. 996-998, Vol. 43, No. 2
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.2.996-998.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

CASE REPORT

Nalidixic Acid-Resistant Salmonella enterica Serotype Typhi Presenting as a Primary Psoas Abscess: Case Report and Review of the Literature

William A. Shakespeare,1 Daniel Davie,2 Claude Tonnerre,3,4 Michael A. Rubin,3,4 Michael Strong,3 and Cathy A. Petti3,4,5*

University of Utah School of Medicine,1 Department of Family Practice,2 Department of Medicine,3 Division of Infectious Diseases,4 Department of Pathology, University of Utah Hospitals and Clinics, Salt Lake City, Utah5

Received 24 April 2004/ Returned for modification 29 May 2004/ Accepted 19 October 2004

We report an unusual case of Salmonella enterica serotype Typhi presenting as a primary psoas abscess. The isolate tested susceptible to ciprofloxacin but resistant to nalidixic acid in vitro, a pattern associated with fluoroquinolone therapeutic failures. We review the literature for serovar Typhi psoas abscess in the absence of bacteremia and discuss the importance of identifying isolates with reduced susceptibility to fluoroquinolones.

* Corresponding author. Mailing address: Department of Pathology, University of Utah Hospitals and Clinics, 500 Chipeta Way, Salt Lake City, UT 84108. Phone: (801) 583-2787, ext. 3174. Fax: (801) 584-5207. E-mail: cathy.petti{at}aruplab.com.

Journal of Clinical Microbiology, February 2005, p. 996-998, Vol. 43, No. 2
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.2.996-998.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Boyle, E. C., Bishop, J. L., Grassl, G. A., Finlay, B. B. (2007). Salmonella: from Pathogenesis to Therapeutics. J. Bacteriol. 189: 1489-1495 [Full Text]  
  • Sivapalasingam, S., Nelson, J. M., Joyce, K., Hoekstra, M., Angulo, F. J., Mintz, E. D. (2006). High Prevalence of Antimicrobial Resistance among Shigella Isolates in the United States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob. Agents Chemother. 50: 49-54 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»